APR 14, 2015 10:22 AM PDT

New Cancer Drug Could Result from 6 Molecules That Block HuR

WRITTEN BY: Will Hector
Scientists have found six molecules that block HuR, an "oncoprotein" linked to cancer that was thought to be "undruggable."

The findings could lead to a new class of cancer drugs, researchers say.

HuR has been detected at high levels in almost every type of cancer tested, including cancers of the colon, prostate, breast, brain, ovaries, pancreas, and lung.

"HuR inhibitors may be useful for many types of cancer," says Liang Xu, associate professor of molecular biosciences at the University of Kansas. "Since HuR is involved in many stem cell pathways, we expect HuR inhibitors will be active in inhibiting ‘cancer stem cells,' or the seeds of cancer, which have been a current focus in the cancer drug discovery field."

HuR has been studied for many years, but until now no direct HuR inhibitors have been discovered.

"The initial compounds reported in this paper can be further optimized and developed as a whole new class of cancer therapy, especially for cancer stem cells," Xu says.

PRECISION MEDICINE
"The success of our study provides a first proof-of-principle that HuR is druggable, which opens a new door for cancer drug discovery. Many other RNA-binding proteins like HuR, which are so far undruggable, can also be tested for drug discovery using our strategy."

For the study, published in ACS Chemical Biology, researchers evaluated about 6,000 compounds from both the KU Chemical Methodologies and Library Development Center and the Food and Drug Administration in a process known as "high throughput screening," hunting for compounds that obstruct HuR's interface with healthy human RNA.

"A cancer-causing gene, or oncogene, makes RNA, which then makes an oncoprotein that causes cancer or makes cancer cells hard to kill, or both," Xu says. "This is the problem we're trying to overcome with precision medicine."

The HuR-RNA binding site is like a long, narrow groove, not a well-defined pocket seen in other druggable proteins targeted by many current cancer therapies.

"HuR tightly binds to RNA like a hand," Xu says. "The HuR protein grabs the ‘rope'-or the RNA-at a site called ‘ARE' on the rope. We aimed to find a small-molecule compound that makes the hand release the rope by competing with ARE of the RNA."

(Sources: University of Kansas; Futurity.org)
About the Author
  • Will Hector practices psychotherapy at Heart in Balance Counseling Center in Oakland, California. He has substantial training in Attachment Theory, Hakomi Body-Centered Psychotherapy, Psycho-Physical Therapy, and Formative Psychology. To learn more about his practice, click here: http://www.heartinbalancetherapy.com/will-hector.html
You May Also Like
AUG 07, 2018
Cancer
AUG 07, 2018
Potential Bcl-2 Targeted Therapy for Relapsed Multiple Myeloma Patients
Targeted therapy for Bcl-2 may be helpful in more than the two lymphoma diagnoses that were recently approved by the FDA....
AUG 10, 2018
Immunology
AUG 10, 2018
Cancer Cell 'Drones' Battle Immune System
Cancer cells release PD-L1 containing exosomes that circulate in the blood and stop T cells before they can reach tumors....
SEP 05, 2018
Videos
SEP 05, 2018
Why Glioblastoma Is So Deadly
Senator John McCain passed away recently after battling brain cancer. Most forms of brain cancer are aggressive and difficult to treat because medications...
SEP 15, 2018
Cancer
SEP 15, 2018
Undescended testicles could lead to testicular cancer and infertility in adult males
An undescended testis (cryptorchidism) is a condition in which one of the testes or both have not descended into the right position in the scrotum at birth and either stay at the abdomen or d...
NOV 02, 2018
Cell & Molecular Biology
NOV 02, 2018
Natural Molecule Enables Obese Mice to Shed Weight
A molecule that has been a focus of cancer research has been found to be a significant regulator of metabolism....
DEC 09, 2018
Immunology
DEC 09, 2018
A Better Human Immune System: In Mice
We've cured cancer and autoimmune disease in mice many times over....
Loading Comments...